New Natural Compound Offers Hope as Obesity Treatment Alternative

Scientists have uncovered a naturally occurring molecule that may serve as a safer option for weight management, potentially outperforming popular drugs like Ozempic and Wegovy. The discovery, facilitated by artificial intelligence, highlights a breakthrough in targeting the brain’s hunger control mechanisms directly.

Targeting the Appetite Center

This molecule, named BRP, functions within the hypothalamus—the brain region responsible for regulating hunger. Unlike existing treatments that act on multiple areas, BRP focuses on the specific pathways associated with appetite, which could minimize common side effects such as nausea and gastrointestinal discomfort.

“The hypothalamus operates as a starvation sensor, determining whether you’re hungry or not,” explained Giles Yeo, a professor at the UK Medical Research Council’s Metabolic Diseases Unit. “It’s trying to detect internal signals: ‘Am I starving? How hungry am I?'”

Current weight-loss injections, including those mimicking the hormone GLP-1, primarily influence the hindbrain to signal satiety. However, this approach often results in side effects like vomiting and constipation. BRP’s unique mechanism may offer a solution by focusing on the hypothalamus, where hunger signals are processed.

A New Pathway for Weight Loss

In animal studies, BRP demonstrated the ability to reduce fat while preserving muscle mass—a contrast to GLP-1 drugs, which sometimes lead to unintended muscle loss. This distinction could make BRP a more balanced option for long-term treatment. “The sheer audacity to sift through thousands of peptides is truly remarkable,” said Randy J. Seeley, a researcher at the University of Michigan. “I’m amazed by the innovation.”

Developed using an AI tool called Peptide Predictor, BRP was identified from over 20,000 human genes. The team narrowed down candidates and tested around 100 before selecting BRP as a promising candidate. Obese mice receiving BRP injections experienced significant weight loss, while those without treatment gained weight.

Challenges and Future Steps

Katrin Svensson, the study’s lead author, has co-founded a company aiming to initiate human trials soon. Yet, translating success from animal models to humans remains uncertain. “The hardest part is knowing if the drug will be safe enough for long-term use,” Seeley noted. “Obesity requires sustained treatment, so safety is critical.”

While GLP-1 drugs are modified versions of a natural hormone, BRP could be engineered similarly to enhance its effectiveness. Even if BRP proves successful, GLP-1 mimics may still hold value due to their additional benefits, such as lowering cardiovascular risks. Yeo believes a broader range of tools will help individuals find the most suitable treatment. “More options mean people can tailor their approach,” he said. “Staying on a drug increases the chance of maintaining weight loss.”